NCT00154375View on ClinicalTrials.gov

Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

August 31, 2008

Conditions
Glioblastoma MultiformeAstrocytoma
Interventions
DRUG

Imatinib mesylate

Imatinib was supplied as 100 mg and 400 mg tablets packaged in polyethylene bottles.

DRUG

Hydroxyurea

Trial Locations (1)

Unknown

Novartis Investigative Site, Dülmen

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY